Phase 3 multicenter, open-label study to investigate the efficacy and safety of Sofosbuvir/Ledipasvir fixed-dose combination for 12 weeks in subjects with chronic genotype 1 or 4 HCV and HIV-1 co-infection
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
March 3, 2014
End Date
March 2, 2016
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
March 3, 2014
End Date
March 2, 2016